Psyence Biomedical (PBM) EBITDA (2023 - 2025)

Psyence Biomedical has reported EBITDA for 3 years, with the latest figure at -$1.5 million in Q3 2025.

• On a quarterly basis, EBITDA fell 230.0% year-over-year to -$1.5 million in Q3 2025; TTM through Sep 2025 was -$3.7 million, a N/A change from a year earlier, with the FY2026 full-year figure at -$6.2 million, down 70.11% from the prior year.
• EBITDA was -$1.5 million for Q3 2025 at Psyence Biomedical, down from $1.2 million in the prior quarter.
• The five-year high for EBITDA was $1.2 million in Q3 2024, with the low at -$3.2 million in Q1 2023.
• Average EBITDA over 3 years is -$928835.7, with a median of -$856580.5 recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA soared 668.75% in 2024, then plunged 230.0% in 2025.
• Over 3 years, EBITDA stood at -$204101.0 in 2023, then jumped by 668.75% to $1.2 million in 2024, then slumped by 230.0% to -$1.5 million in 2025.
• The last three EBITDA figures came in at -$1.5 million (Q3 2025), $1.2 million (Q3 2024), and -$204101.0 (Q3 2023), per Business Quant data.